{"id":68946,"date":"2024-06-13T09:32:18","date_gmt":"2024-06-13T14:32:18","guid":{"rendered":"https:\/\/www.partnershipagainstcancer.ca\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/"},"modified":"2024-06-13T11:52:05","modified_gmt":"2024-06-13T16:52:05","slug":"time-to-diagnosis","status":"publish","type":"topics","link":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/","title":{"rendered":"D\u00e9lai entre le d\u00e9pistage et le diagnostic"},"content":{"rendered":"<p><strong>Pourquoi est-ce important? <\/strong>Une r\u00e9ponse diagnostique rapide et bien coordonn\u00e9e \u00e0 la suite d\u2019un r\u00e9sultat anormal de d\u00e9pistage du cancer du sein est essentielle, une \u00e9valuation diagnostique tardive pouvant aggraver le pronostic et r\u00e9duire les chances de survie<sup>1<\/sup>. Toutes les personnes qui obtiennent un r\u00e9sultat de d\u00e9pistage anormal ne re\u00e7oivent pas n\u00e9cessairement un diagnostic de cancer du sein. Un diagnostic confirm\u00e9 n\u00e9cessite des proc\u00e9dures diagnostiques suppl\u00e9mentaires, par exemple un examen d\u2019imagerie, une microbiopsie, une biopsie chirurgicale ou une biopsie par aspiration \u00e0 l\u2019aiguille fine. Plusieurs facteurs peuvent se r\u00e9percuter sur l\u2019intervalle diagnostique, c\u2019est-\u00e0-dire la dur\u00e9e entre la notification d\u2019un r\u00e9sultat de d\u00e9pistage anormal et le diagnostic d\u00e9finitif, notamment le type d\u2019analyses diagnostiques effectu\u00e9es et la capacit\u00e9 des programmes de d\u00e9pistage provinciaux et territoriaux, ainsi que des facteurs li\u00e9s \u00e0 la personne participant au programme, comme sa situation g\u00e9ographique et la complexit\u00e9 du cas. Cet indicateur peut \u00eatre am\u00e9lior\u00e9 gr\u00e2ce \u00e0 une orientation efficace des personnes participant au programme, \u00e0 l\u2019int\u00e9gration de routines de soins, \u00e0 une meilleure coordination des aiguillages et \u00e0 un traitement acc\u00e9l\u00e9r\u00e9 des cas en fonction de la gravit\u00e9 de la maladie<sup>2<\/sup>.<\/p>\n<p><strong>D\u00e9finition de l\u2019indicateur\u00a0<\/strong>: Pourcentage de personnes participant au programme ayant re\u00e7u un diagnostic dans les d\u00e9lais cibles suivants.<\/p>\n<ul>\n<li>5\u00a0semaines pour un diagnostic n\u2019ayant pas n\u00e9cessit\u00e9 de biopsie tissulaire<\/li>\n<li>7\u00a0semaines pour un diagnostic ayant n\u00e9cessit\u00e9 une biopsie tissulaire<\/li>\n<\/ul>\n<p><strong>Cible\u00a0<\/strong>:<\/p>\n<ul>\n<li>Sans biopsie tissulaire\u00a0&#8211;\u00a0\u2265\u00a090\u00a0% des diagnostics dans un d\u00e9lai de\u00a05\u00a0semaines<\/li>\n<li>Avec biopsie tissulaire\u00a0&#8211;\u00a0\u2265\u00a090\u00a0% des diagnostics dans un d\u00e9lai de\u00a07\u00a0semaines<\/li>\n<\/ul>\n<p><strong>P\u00e9riode de mesure\u00a0<\/strong>:<\/p>\n<ul>\n<li>1<sup>er<\/sup> janvier\u00a02019 au\u00a031\u00a0d\u00e9cembre\u00a02019<\/li>\n<li>1<sup>er<\/sup> janvier\u00a02020 au\u00a031\u00a0d\u00e9cembre\u00a02020<\/li>\n<\/ul>\n<p><strong>Calcul de l\u2019indicateur <\/strong>:<\/p>\n<ul>\n<li><strong>Sans biopsie tissulaire<\/strong>\n<ul>\n<li>Num\u00e9rateur\u00a0: Nombre de diagnostics confirm\u00e9s obtenus dans les\u00a05\u00a0semaines suivant la date du d\u00e9pistage<\/li>\n<li>D\u00e9nominateur : Nombre total de d\u00e9pistages anormaux au cours de la p\u00e9riode de mesure, pour lesquels on n\u2019a pas effectu\u00e9 de biopsie tissulaire<\/li>\n<\/ul>\n<\/li>\n<li><strong>Avec biopsie tissulaire<\/strong>\n<ul>\n<li>Num\u00e9rateur : Nombre de diagnostics confirm\u00e9s obtenus dans les 7 semaines suivant la date du d\u00e9pistage<\/li>\n<li>D\u00e9nominateur\u00a0: Nombre total de d\u00e9pistages anormaux au cours de la p\u00e9riode de mesure, pour lesquels on a effectu\u00e9 une biopsie tissulaire<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Consid\u00e9rations li\u00e9es \u00e0 la COVID-19\u00a0<\/strong>: Bien que les services de d\u00e9pistage et de diagnostic du cancer du sein aient repris, la suspension temporaire des proc\u00e9dures de d\u00e9pistage et de diagnostic du cancer du sein au d\u00e9but de la pand\u00e9mie a perturb\u00e9 les diagnostics. En observant la tendance mensuelle du nombre de diagnostics de cancer du sein, on constate <a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/cancer-in-covid-19-era\/current-state\/impacts-diagnoses\/\">une baisse de\u00a031\u00a0% des diagnostics de nouveaux cas de cancer du sein<\/a> en avril\u00a02020 par rapport \u00e0 la moyenne\u00a02015-2019. Il est important que les programmes de d\u00e9pistage du cancer du sein et les services de diagnostic utilisent des strat\u00e9gies adapt\u00e9es comme des approches bas\u00e9es sur les risques, pour r\u00e9duire les retards dans les services de diagnostic.<\/p>\n<p><a name=\"time-5w\"><\/a><\/p>\n<h3>Pourcentage de d\u00e9pistages anormaux chez les personnes \u00e2g\u00e9es de 50\u00a0\u00e0\u00a074\u00a0ans ayant re\u00e7u un diagnostic d\u00e9finitif sans biopsie dans les 5\u00a0semaines, par territoire de comp\u00e9tence \u2013 2019 et 2020<\/h3>\n<p><link rel='stylesheet' href='https:\/\/cdnjs.cloudflare.com\/ajax\/libs\/font-awesome\/4.7.0\/css\/font-awesome.min.css'><link rel='stylesheet' href='https:\/\/www.partnershipagainstcancer.ca\/wp-content\/plugins\/cpac-toolbox\/cpac-toolbox.css?v2'><script type='text\/javascript' src='https:\/\/www.partnershipagainstcancer.ca\/wp-content\/plugins\/cpac-toolbox\/cpac-toolbox.js?v2'><\/script><style>\niframe.cpac-dashboard { .statusBar{display:none;}\r\npbi-status-bar{opacity:0.1;background: white;height: 0;}\r\n.backgroundContainer.outspaceContainer{background:#fff!important;} }\n<\/style><div class='cpac-dashboard-container'><iframe allowfullscreen='allowfullscreen' title='cpac-dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145' id='dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145' src='https:\/\/dashboard.cpacc.ca\/report\/eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9&language=fr-CA' class='cpac-dashboard'  style='width:100%'><\/iframe><\/div><script>\n                    var is_fullreport = 0;\n                    var scrolled = false;\n                    window.addEventListener('message', function(e){\n                            var this_frame = document.getElementById('dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145');\n\n\t\t\t            \/\/ Extract token from parent src\n    \t\t\t        var parentToken = this_frame.src.split('\/').pop();\n\t\t\t\tparentToken = parentToken.split('&')[0];\n\n\/\/                            console.log(JSON.stringify(e.data));\n                    \tif (e.data && e.data.hasOwnProperty('cpac_height') && \n                            e.data.hasOwnProperty('iframe_token') && \n                            e.data.iframe_token === parentToken && \n                            e.origin == 'https:\/\/dashboard.cpacc.ca') { \n                            \n                            console.log('cpac-dashboard: resizing iframe height to ' + e.data.cpac_height + ' for id=dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145[' + e.origin + ']' );\n\/\/                                this_frame.height = e.data.cpac_height + 'px';\n                            \n                            if(is_fullreport){\n                                this_frame.style.height = e.data.cpac_height + 'px';\n                            }else if(e.data.cpac_height>200 && e.data.cpac_height<1000){\n                                \/\/ if height = 401px then style.height = 410px\n                                \/\/ if height = 373px then style.height = 380px\n                                \/\/ if height = 350px then style.height = 350px\n                                const cpac_height = (parseInt(e.data.cpac_height\/10)+((e.data.cpac_height%10>0)?1:0))*10;\n                                this_frame.style.height = cpac_height + 'px';\n                            }else{\n                                this_frame.style.height = '500px';\n                            }\n                        }\n\n                            if (e.data && e.data.hasOwnProperty('target_element_y') && e.origin == 'https:\/\/dashboard.cpacc.ca' && !scrolled) {\n                                console.log('received element >>>'+e.data.target_element_y);\n                                let targetYFromDoc = 0;\n                                let element = document.getElementById('dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145');\n                                while(element){\n                                    targetYFromDoc += parseInt(element.offsetTop - element.scrollTop + element.clientTop);\n                                    element = element.offsetParent;\n                                }\n                                targetYFromDoc += parseInt(e.data.target_element_y?e.data.target_element_y:0);\n                                window.scrollTo({top: targetYFromDoc, behavior: 'smooth'});\n                                scrolled = true;\n                            }\n                        });\n                        var frame_eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145 = document.getElementById('dashboard-eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145');\n                        frame_eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145.onload = function() {\n                            const styleCode = '.statusBar{display:none;}pbi-status-bar{opacity:0.1;background:white;height:0;}.backgroundContainer.outspaceContainer{background:#fff!important;}';\n                            frame_eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145.contentWindow.postMessage({'style':styleCode ,'value':'sendStyle'},'*');\n                            const targetId = 'null';\n                            frame_eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145.contentWindow.postMessage({'targetId':targetId,'value':'requestTargetPosition'},'*');\n                            const selectBoxId = 'null';\n                            const selectBoxValue = '1';\n                            frame_eyJrIjoiMmEzOTI4NjgtNTU4MC00ZjUzLWE2MjEtZDgyNjRhNTdhNzYzIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_145.contentWindow.postMessage({'selectBoxId':selectBoxId,'selectBoxValue':selectBoxValue,'value':'requestTargetSelectBoxTrigger'},'*');\n                        };\n                    <\/script><br \/>\n<a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/data-tables-breast-indicators\/#time-5w\"><br \/>\n<sub>Tableau de donn\u00e9es et notes de bas de page<\/sub><\/a><\/p>\n<p>Le pourcentage de personnes pr\u00e9sentant des r\u00e9sultats de d\u00e9pistage anormaux qui ont re\u00e7u un diagnostic d\u00e9finitif dans les 5\u00a0semaines sans biopsie variait de 70,4\u00a0% \u00e0 l\u2019\u00cele-du-Prince-\u00c9douard \u00e0 94,9\u00a0% en Alberta, en 2019, et de 73\u00a0% au Nouveau-Brunswick \u00e0 93,8\u00a0% en Alberta, en 2020. L\u2019Alberta et l\u2019Ontario sont les seules provinces \u00e0 avoir atteint l\u2019objectif (\u2265\u00a090\u00a0%) en 2019 et en 2020. Bien que la plupart des territoires de comp\u00e9tence n\u2019aient pas atteint l\u2019objectif (\u2265\u00a090\u00a0%), le rendement de cet indicateur au sein des territoires de comp\u00e9tence s\u2019est l\u00e9g\u00e8rement am\u00e9lior\u00e9 ou est rest\u00e9 relativement constant entre 2019 et 2020.<br \/>\n<a name=\"time-7w\"><\/a><\/p>\n<h3>Pourcentage de d\u00e9pistages anormaux chez les personnes \u00e2g\u00e9es de 50 \u00e0 74 ans ayant re\u00e7u un diagnostic d\u00e9finitif avec biopsie dans les 7 semaines, par territoire de comp\u00e9tence \u2013 2019 et 2020<\/h3>\n<p><link rel='stylesheet' href='https:\/\/cdnjs.cloudflare.com\/ajax\/libs\/font-awesome\/4.7.0\/css\/font-awesome.min.css'><link rel='stylesheet' href='https:\/\/www.partnershipagainstcancer.ca\/wp-content\/plugins\/cpac-toolbox\/cpac-toolbox.css?v2'><script type='text\/javascript' src='https:\/\/www.partnershipagainstcancer.ca\/wp-content\/plugins\/cpac-toolbox\/cpac-toolbox.js?v2'><\/script><style>\niframe.cpac-dashboard { .statusBar{display:none;}\r\npbi-status-bar{opacity:0.1;background: white;height: 0;}\r\n.backgroundContainer.outspaceContainer{background:#fff!important;} }\n<\/style><div class='cpac-dashboard-container'><iframe allowfullscreen='allowfullscreen' title='cpac-dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676' id='dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676' src='https:\/\/dashboard.cpacc.ca\/report\/eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9&language=fr-CA' class='cpac-dashboard'  style='width:100%'><\/iframe><\/div><script>\n                    var is_fullreport = 0;\n                    var scrolled = false;\n                    window.addEventListener('message', function(e){\n                            var this_frame = document.getElementById('dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676');\n\n\t\t\t            \/\/ Extract token from parent src\n    \t\t\t        var parentToken = this_frame.src.split('\/').pop();\n\t\t\t\tparentToken = parentToken.split('&')[0];\n\n\/\/                            console.log(JSON.stringify(e.data));\n                    \tif (e.data && e.data.hasOwnProperty('cpac_height') && \n                            e.data.hasOwnProperty('iframe_token') && \n                            e.data.iframe_token === parentToken && \n                            e.origin == 'https:\/\/dashboard.cpacc.ca') { \n                            \n                            console.log('cpac-dashboard: resizing iframe height to ' + e.data.cpac_height + ' for id=dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676[' + e.origin + ']' );\n\/\/                                this_frame.height = e.data.cpac_height + 'px';\n                            \n                            if(is_fullreport){\n                                this_frame.style.height = e.data.cpac_height + 'px';\n                            }else if(e.data.cpac_height>200 && e.data.cpac_height<1000){\n                                \/\/ if height = 401px then style.height = 410px\n                                \/\/ if height = 373px then style.height = 380px\n                                \/\/ if height = 350px then style.height = 350px\n                                const cpac_height = (parseInt(e.data.cpac_height\/10)+((e.data.cpac_height%10>0)?1:0))*10;\n                                this_frame.style.height = cpac_height + 'px';\n                            }else{\n                                this_frame.style.height = '500px';\n                            }\n                        }\n\n                            if (e.data && e.data.hasOwnProperty('target_element_y') && e.origin == 'https:\/\/dashboard.cpacc.ca' && !scrolled) {\n                                console.log('received element >>>'+e.data.target_element_y);\n                                let targetYFromDoc = 0;\n                                let element = document.getElementById('dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676');\n                                while(element){\n                                    targetYFromDoc += parseInt(element.offsetTop - element.scrollTop + element.clientTop);\n                                    element = element.offsetParent;\n                                }\n                                targetYFromDoc += parseInt(e.data.target_element_y?e.data.target_element_y:0);\n                                window.scrollTo({top: targetYFromDoc, behavior: 'smooth'});\n                                scrolled = true;\n                            }\n                        });\n                        var frame_eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676 = document.getElementById('dashboard-eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676');\n                        frame_eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676.onload = function() {\n                            const styleCode = '.statusBar{display:none;}pbi-status-bar{opacity:0.1;background:white;height:0;}.backgroundContainer.outspaceContainer{background:#fff!important;}';\n                            frame_eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676.contentWindow.postMessage({'style':styleCode ,'value':'sendStyle'},'*');\n                            const targetId = 'null';\n                            frame_eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676.contentWindow.postMessage({'targetId':targetId,'value':'requestTargetPosition'},'*');\n                            const selectBoxId = 'null';\n                            const selectBoxValue = '1';\n                            frame_eyJrIjoiMzg2ZGU0Y2UtMjU0ZC00MGZkLWE4NTAtNzI4YjIwYmQwMmFjIiwidCI6ImQxODkwM2ZiLTk2OTMtNDMyZC1iMDA0LTI3M2I3MDE1NDQ5MCJ9_676.contentWindow.postMessage({'selectBoxId':selectBoxId,'selectBoxValue':selectBoxValue,'value':'requestTargetSelectBoxTrigger'},'*');\n                        };\n                    <\/script><br \/>\n<a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/data-tables-breast-indicators\/#time-7w\"><sub>Tableau de donn\u00e9es et notes de bas de page<\/sub><\/a><\/p>\n<p>Le pourcentage de personnes pr\u00e9sentant des r\u00e9sultats de d\u00e9pistage anormaux pour lesquelles une biopsie s\u2019est av\u00e9r\u00e9e n\u00e9cessaire et qui ont re\u00e7u un diagnostic d\u00e9finitif dans les 7\u00a0semaines variait de 47,6\u00a0% \u00e0 91,5\u00a0%, en 2019, et de 53,7\u00a0% \u00e0 93,2\u00a0%, en 2020. L\u2019Alberta a \u00e9t\u00e9 la seule province \u00e0 atteindre l\u2019objectif national (\u2265\u00a090\u00a0%) en 2019 et en 2020.<\/p>\n<div style=\"height: 40px; width: 100%;\"><\/div>\n<style>.cpac-dashboard-container {margin-bottom: -60px;}<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Pourquoi est-ce important? Une r\u00e9ponse diagnostique rapide et bien coordonn\u00e9e \u00e0 la suite d\u2019un r\u00e9sultat anormal de d\u00e9pistage du cancer du sein est essentielle, une \u00e9valuation diagnostique tardive pouvant aggraver le pronostic et r\u00e9duire les chances de survie1. Toutes les personnes qui obtiennent un r\u00e9sultat de d\u00e9pistage anormal ne re\u00e7oivent pas n\u00e9cessairement un diagnostic de [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":68910,"menu_order":5,"template":"","topics_tags":[],"type-of-care":[],"cancer-continuum":[],"cancer-system-measurement":[],"dbt-cancer-site":[],"dbt-risk-factors":[],"dbt-population-characteristics":[],"class_list":["post-68946","topics","type-topics","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canadian Partnership Against Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9lai entre le d\u00e9pistage et le diagnostic - Canadian Partnership Against Cancer\" \/>\n<meta property=\"og:description\" content=\"Pourquoi est-ce important? Une r\u00e9ponse diagnostique rapide et bien coordonn\u00e9e \u00e0 la suite d\u2019un r\u00e9sultat anormal de d\u00e9pistage du cancer du sein est essentielle, une \u00e9valuation diagnostique tardive pouvant aggraver le pronostic et r\u00e9duire les chances de survie1. Toutes les personnes qui obtiennent un r\u00e9sultat de d\u00e9pistage anormal ne re\u00e7oivent pas n\u00e9cessairement un diagnostic de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Partnership Against Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-13T16:52:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@cancerstratca\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/time-to-diagnosis\\\/\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/time-to-diagnosis\\\/\",\"name\":\"D\u00e9lai entre le d\u00e9pistage et le diagnostic - Canadian Partnership Against Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\"},\"datePublished\":\"2024-06-13T14:32:18+00:00\",\"dateModified\":\"2024-06-13T16:52:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/time-to-diagnosis\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/time-to-diagnosis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/time-to-diagnosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Topics\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/topics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Surveillance et \u00e9valuation des indicateurs de la qualit\u00e9 du d\u00e9pistage du cancer du sein\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Indicateurs\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/indicators\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"D\u00e9lai entre le d\u00e9pistage et le diagnostic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\",\"url\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/\",\"name\":\"Canadian Partnership Against Cancer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canadian Partnership Against Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/","og_locale":"fr_FR","og_type":"article","og_title":"D\u00e9lai entre le d\u00e9pistage et le diagnostic - Canadian Partnership Against Cancer","og_description":"Pourquoi est-ce important? Une r\u00e9ponse diagnostique rapide et bien coordonn\u00e9e \u00e0 la suite d\u2019un r\u00e9sultat anormal de d\u00e9pistage du cancer du sein est essentielle, une \u00e9valuation diagnostique tardive pouvant aggraver le pronostic et r\u00e9duire les chances de survie1. Toutes les personnes qui obtiennent un r\u00e9sultat de d\u00e9pistage anormal ne re\u00e7oivent pas n\u00e9cessairement un diagnostic de [&hellip;]","og_url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/","og_site_name":"Canadian Partnership Against Cancer","article_publisher":"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/","article_modified_time":"2024-06-13T16:52:05+00:00","twitter_card":"summary_large_image","twitter_site":"@cancerstratca","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/","url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/","name":"D\u00e9lai entre le d\u00e9pistage et le diagnostic - Canadian Partnership Against Cancer","isPartOf":{"@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website"},"datePublished":"2024-06-13T14:32:18+00:00","dateModified":"2024-06-13T16:52:05+00:00","breadcrumb":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/time-to-diagnosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Topics","item":"https:\/\/www.partnershipagainstcancer.ca\/topics\/"},{"@type":"ListItem","position":2,"name":"Surveillance et \u00e9valuation des indicateurs de la qualit\u00e9 du d\u00e9pistage du cancer du sein","item":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/"},{"@type":"ListItem","position":3,"name":"Indicateurs","item":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/indicators\/"},{"@type":"ListItem","position":4,"name":"D\u00e9lai entre le d\u00e9pistage et le diagnostic"}]},{"@type":"WebSite","@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website","url":"https:\/\/dev.partnershipagainstcancer.ca\/","name":"Canadian Partnership Against Cancer","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.partnershipagainstcancer.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/68946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/types\/topics"}],"author":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/users\/24"}],"up":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/68910"}],"wp:attachment":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=68946"}],"wp:term":[{"taxonomy":"topics_tags","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics_tags?post=68946"},{"taxonomy":"type-of-care","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/type-of-care?post=68946"},{"taxonomy":"cancer-continuum","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-continuum?post=68946"},{"taxonomy":"cancer-system-measurement","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-system-measurement?post=68946"},{"taxonomy":"dbt-cancer-site","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-cancer-site?post=68946"},{"taxonomy":"dbt-risk-factors","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-risk-factors?post=68946"},{"taxonomy":"dbt-population-characteristics","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-population-characteristics?post=68946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}